|
Patent landscape, scope, and claims: |
Analysis of U.S. Patent 6,294,548: Formulations and Methods for Treating Inflammatory Conditions
U.S. Patent 6,294,548, granted on September 25, 2001, to The Board of Trustees of the Leland Stanford Junior University, covers specific pharmaceutical compositions and methods for treating inflammatory conditions. The patent's claims focus on the use of particular types of pharmaceutical formulations, primarily involving modified release of an active pharmaceutical ingredient, aimed at managing inflammation. The patent landscape surrounding this technology involves other entities and patents that may relate to similar therapeutic areas or formulation technologies.
What is the core invention protected by U.S. Patent 6,294,548?
The primary invention disclosed in U.S. Patent 6,294,548 pertains to pharmaceutical compositions designed for the treatment of inflammatory conditions. Specifically, the patent details formulations that enable modified release of an active agent. The disclosed formulations are intended to provide a sustained or controlled delivery of the therapeutic compound, thereby improving efficacy and potentially reducing side effects associated with rapid drug release. The patent emphasizes a particular type of matrix system where the active ingredient is dispersed within a specific polymer matrix.
What specific inflammatory conditions does the patent address?
The patent broadly addresses "inflammatory conditions." While not exhaustively listing every possible condition, the disclosure provides examples and context suggesting applicability to conditions characterized by inflammation, such as:
- Rheumatoid arthritis
- Osteoarthritis
- Inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)
- Psoriasis
- Asthma
- Allergic rhinitis
The mechanism of action for the active ingredients contemplated within these formulations typically targets inflammatory pathways.
What are the key claims of U.S. Patent 6,294,548?
U.S. Patent 6,294,548 has several independent and dependent claims that define the scope of the invention. The most significant claims focus on the composition of the pharmaceutical formulations.
Claim 1: Pharmaceutical Compositions
Independent Claim 1 defines a pharmaceutical composition comprising:
- An active ingredient in a therapeutically effective amount.
- A pharmaceutically acceptable matrix material.
The key defining characteristic of the matrix material is that it is a biocompatible polymer that does not degrade in vivo, but rather erodes or dissolves in vivo to release the active ingredient. This distinguishes it from biodegradable matrix systems. The active ingredient is dispersed within this matrix material.
- Key characteristics of the matrix material as per the patent:
- Non-degradable in vivo.
- Erodes or dissolves in vivo.
- Biocompatible.
- Examples of such materials include poly(alkyl cyanoacrylate) and poly(ester amide)s.
Claim 5: Method of Treatment
Independent Claim 5 claims a method for treating an inflammatory condition in a subject. This method involves:
- Administering to the subject a pharmaceutical composition as defined in Claim 1.
- The administration is for a duration sufficient to achieve therapeutic benefit.
The method leverages the modified release properties of the claimed composition to provide sustained therapeutic levels of the active agent.
Dependent Claims
The patent includes numerous dependent claims that further limit and define aspects of the invention. These claims may specify:
- The type and concentration of the active ingredient.
- The specific class or chemical structure of the matrix material (e.g., specifying particular polymers).
- The physical form of the composition (e.g., tablets, capsules).
- The rate or profile of drug release (e.g., a specific release half-life or percentage released over time).
- Specific inflammatory conditions for which the composition is intended.
- Routes of administration (e.g., oral, parenteral).
For example, dependent claims might specify that the matrix material is a block copolymer or that the active ingredient is a non-steroidal anti-inflammatory drug (NSAID) or a corticosteroid.
What is the patent landscape surrounding U.S. Patent 6,294,548?
The patent landscape for inflammatory condition treatments and pharmaceutical formulations is extensive. U.S. Patent 6,294,548 exists within a broader ecosystem of intellectual property covering active pharmaceutical ingredients (APIs), therapeutic uses, and drug delivery technologies.
Related Technologies and Patent Areas
- Active Pharmaceutical Ingredients (APIs): Patents covering specific drugs used to treat inflammation (e.g., biologics, small molecule inhibitors) are foundational. U.S. Patent 6,294,548 would typically be licensed or practiced in conjunction with patents covering the API itself.
- Modified Release Formulations: A significant body of patents exists for various modified release technologies, including sustained-release, controlled-release, and delayed-release formulations. These can involve different mechanisms like diffusion, osmosis, or degradation of matrix materials. Patents in this area may claim specific polymer compositions, manufacturing processes, or release profiles.
- Delivery Systems: Beyond matrix formulations, other delivery systems for anti-inflammatory agents are patented, such as liposomes, nanoparticles, implants, and transdermal patches.
- Specific Therapeutic Uses: Patents may claim the use of existing drugs for new indications or specific patient populations within the realm of inflammatory diseases.
Potential Competitors and Overlapping Patents
Analyzing the competitive landscape requires identifying companies and institutions that have filed patents in similar areas. This includes:
- Major pharmaceutical companies: Companies with extensive R&D in inflammation (e.g., AbbVie, Pfizer, Johnson & Johnson, Merck) hold numerous patents in this therapeutic area, including formulation patents.
- Biotechnology companies: Companies specializing in biologics for inflammatory diseases (e.g., Amgen, Regeneron) also contribute significantly to the patent landscape.
- Specialty formulation companies: Some companies focus specifically on drug delivery technologies and may have patents on novel matrices or release mechanisms.
- Academic institutions: Universities like Stanford (the assignee of 6,294,548) are significant sources of foundational research and early-stage patent filings.
Patent Analysis and Freedom-to-Operate Considerations
For a company looking to develop or market a product based on the technology in U.S. Patent 6,294,548, a thorough freedom-to-operate (FTO) analysis is critical. This involves:
- Claim Interpretation: Precisely defining the scope of claims in U.S. Patent 6,294,548 and any related patents.
- Product Comparison: Comparing the proposed product's composition and functionality against the interpreted claims of existing patents.
- Prior Art Search: Identifying any prior art that may invalidate existing patents, including U.S. Patent 6,294,548 itself, potentially opening up the technology space.
- Infringement Risk Assessment: Evaluating the likelihood of infringing any valid and in-force patents.
Companies must consider not only direct infringement of U.S. Patent 6,294,548 but also potential infringement of other patents covering APIs, manufacturing processes, or alternative delivery methods for anti-inflammatory agents.
What is the commercial significance and potential impact of this patent?
The commercial significance of U.S. Patent 6,294,548 is tied to its contribution to modified-release drug delivery for inflammatory conditions. Modified-release formulations offer several advantages that can translate into market value:
- Improved Patient Compliance: Less frequent dosing can lead to better adherence to treatment regimens, especially for chronic inflammatory diseases.
- Reduced Side Effects: By controlling the rate of drug release, peak plasma concentrations are often minimized, which can reduce dose-dependent toxicity and side effects.
- Enhanced Therapeutic Efficacy: Maintaining consistent therapeutic drug levels over longer periods can lead to more stable disease control and improved outcomes.
- Potential for Lifecycle Management: For pharmaceutical companies, developing novel formulations can extend the commercial life of an existing drug after its initial patent expires.
The patent's focus on non-degradable, eroding matrices represents a specific approach to controlled release, potentially offering distinct advantages over other methods depending on the API and therapeutic target.
Impact on R&D and Investment Decisions
For R&D departments, this patent signifies a specific technological approach to drug delivery that may be explored for new product development or as a foundation for improving existing anti-inflammatory therapies. Investment decisions would hinge on:
- The strength and validity of the patent: A thorough patentability and validity search would be required.
- The breadth of the claims: Narrow claims may limit the commercial opportunity.
- The therapeutic potential of APIs that can be formulated using this technology: The value of the formulation is intrinsically linked to the efficacy and market potential of the API it carries.
- The competitive landscape: The presence of numerous other patents and products in the inflammatory disease space will influence market entry strategies.
- The manufacturing feasibility and cost-effectiveness: The practicality of producing these formulations at scale is a critical consideration.
What are the future implications and potential challenges?
The future implications of U.S. Patent 6,294,548 and similar patents in modified-release technology are significant.
Future R&D Directions
- Combination Therapies: Formulations may be developed to deliver combinations of APIs targeting different inflammatory pathways simultaneously.
- Personalized Medicine: Modified-release systems could be tailored to individual patient pharmacokinetics, optimizing drug delivery for specific needs.
- New Material Development: Research will continue to focus on developing novel biocompatible matrix materials with even more precise control over drug release kinetics.
- Biologics Delivery: Adapting such formulation technologies for the delivery of larger, more sensitive biologic drugs will be an ongoing area of innovation.
Potential Challenges
- Patent Expiration: U.S. Patent 6,294,548 has an expiration date (typically 20 years from the filing date, with potential extensions). Once expired, the technology enters the public domain, allowing generic competition.
- Technological Obsolescence: Newer, more advanced drug delivery technologies could emerge, making the approach described in this patent less competitive.
- Regulatory Hurdles: Obtaining regulatory approval for any new drug formulation, even one based on established technology, requires extensive clinical trials to demonstrate safety and efficacy.
- Manufacturing Complexity: Some modified-release technologies can be more complex and costly to manufacture than immediate-release formulations, impacting market pricing and accessibility.
- Litigation and Enforcement: Patent holders may face challenges in enforcing their patent rights against alleged infringers, which can lead to costly legal battles.
Key Takeaways
U.S. Patent 6,294,548 protects specific pharmaceutical formulations utilizing non-degradable, eroding biocompatible polymer matrices for the modified release of active agents to treat inflammatory conditions. The patent's claims define the composition and method of use, aiming to improve therapeutic outcomes through controlled drug delivery. The patent landscape is dense, requiring comprehensive freedom-to-operate analyses for any commercial development. The commercial significance lies in the potential for enhanced patient compliance, reduced side effects, and improved efficacy, though its market impact is subject to patent expiration, technological advancements, and regulatory approval processes.
FAQs
-
When does U.S. Patent 6,294,548 expire?
U.S. Patent 6,294,548 was granted on September 25, 2001. U.S. patent terms are generally 20 years from the filing date, subject to potential extensions for patent term adjustment and other provisions. The original filing date for this patent family was December 17, 1999. Therefore, the patent is expected to have expired around December 2019, or potentially later if patent term extensions were granted.
-
What types of active pharmaceutical ingredients (APIs) are envisioned by the patent?
The patent mentions "an active ingredient" without limiting it to a specific class. However, the context of treating "inflammatory conditions" suggests that APIs commonly used for such purposes are contemplated, including non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and potentially newer targeted therapies for inflammatory pathways.
-
Can I manufacture a formulation using the principles of U.S. Patent 6,294,548 after its expiration?
Once a patent expires, the technology described within its claims enters the public domain. This means that, in principle, individuals and companies are free to practice the invention without obtaining a license or paying royalties. However, it is crucial to ensure that the specific formulation or method does not infringe on other, still-active patents.
-
What is the primary advantage of the matrix material described in the patent?
The primary advantage of the matrix material, as described in the patent, is its ability to provide modified release of the active ingredient through erosion or dissolution in vivo, while itself being non-degradable. This allows for sustained and controlled delivery of the drug, which can lead to more consistent therapeutic levels, reduced dosing frequency, and potentially fewer side effects compared to immediate-release formulations.
-
Are there any known drugs currently on the market that utilize the exact formulation technology described in U.S. Patent 6,294,548?
Determining if specific marketed drugs utilize the exact formulation technology of U.S. Patent 6,294,548 requires a detailed analysis of the drug's formulation patents and composition of matter patents. The patent assignee, Stanford University, may have licensed the technology to pharmaceutical companies. Independent confirmation would necessitate a review of approved drug formulations and their associated intellectual property.
Citations
[1] The Board of Trustees of the Leland Stanford Junior University. (2001, September 25). U.S. Patent 6,294,548: Pharmaceutical compositions and methods for treating inflammatory conditions. United States Patent and Trademark Office.
More… ↓
⤷ Start Trial
|
